Drugs / fluticasone propionate/salmeterol
last change Mar 2010 re-read 2 minutes ago

fluticasone propionate/salmeterol

Developed for
chronic obstructive pulmonary disease
Investigated by
GlaxoSmithKline · The Korean Academy of Tuberculosis and Respiratory Diseases

Trials 1 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT00864812 Mar 2009 → Mar 2010 chronic obstructive pulmonary disease The Korean Academy of Tuberculosis and Respiratory Diseases Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as fluticasone propionate/salmeterol ClinicalTrials.gov intervention name — accepted as the source's own label NCT00864812
Known as fluticasone propionate/salmeterol (FSC): Seretide fluticasone propionate/salmeterol (FSC): SeretideNCT00864812
Known as FSC “tiotropium with fluticasone propionate/salmeterol (FSC)” NCT00864812